The FDA's approval of SMA treatment Itvisma marks an "important moment" for the SMA community, a Novartis executive says.

Elevated PD-1+CD4+ T cells represent an independent risk factor for lupus nephritis (LN) and may serve as a biologically meaningful diagnostic and therapeutic target.

Scientists found altered activity of the PUM1 protein plays a key role in pulmonary hypertension development, making it a PH ...

Most studies rely on forever chemicals detected late in pregnancy or cell models, so do not reflect real-life exposure ...

The Wistar Institute has appointed Vincent Wu, PhD, as a Caspar Wistar Fellow in its Vaccine & Immunotherapy Center, bringing ...

Clene is planning to submit an application to the FDA in early 2026 requesting the accelerated approval of CNM-Au8 for ALS.

“By accelerating the production and sharing of trustworthy data, as we are doing at MassCPR, we can empower the public with ...

Glioblastoma is one of the most lethal brain cancers known, and for decades treatment has barely budged survival curves ...

INmune Bio, Inc. (NASDAQ: INMB) ('INmune” or the 'Company”), a clinical-stage inflammation and immunology company, announces a recently published overview of future applications and research areas for ...

An evolutionary perspective on immune priming across plants and invertebrates highlights the roles of microbiomes and epigenetic regulation in shaping innate immune memory with promising applications ...

Ovarian cancer remains an unmet medical need, and experts call for new strategies to define and treat platinum resistance in patients with advanced ovarian cancer[1],[2],[3] ...